

**American
National
Standard**

ANSI/AAMI/ISO 14155-1:2003

**Clinical investigation of medical
devices for human subjects—
Part 1: General requirements**

The Objectives and Uses of AAMI Standards and Recommended Practices

It is most important that the objectives and potential uses of an AAMI product standard or recommended practice are clearly understood. The objectives of AAMI's technical development program derive from AAMI's overall mission: the advancement of medical instrumentation. Essential to such advancement are (1) a continued increase in the safe and effective application of current technologies to patient care, and (2) the encouragement of new technologies. It is AAMI's view that standards and recommended practices can contribute significantly to the advancement of medical instrumentation, provided that they are drafted with attention to these objectives and provided that arbitrary and restrictive uses are avoided.

A voluntary *standard* for a *medical device* recommends to the manufacturer the information that should be provided with or on the product, basic safety and performance criteria that should be considered in qualifying the device for clinical use, and the measurement techniques that can be used to determine whether the device conforms with the safety and performance criteria and/or to compare the performance characteristics of different products. Some standards emphasize the information that should be provided with the device, including performance characteristics, instructions for use, warnings and precautions, and other data considered important in ensuring the safe and effective use of the device in the clinical environment. Recommending the disclosure of performance characteristics often necessitates the development of specialized test methods to facilitate uniformity in reporting; reaching consensus on these tests can represent a considerable part of committee work. When a drafting committee determines that clinical concerns warrant the establishment of *minimum* safety and performance criteria, referee tests must be provided and the reasons for establishing the criteria must be documented in the rationale.

A *recommended practice* provides guidelines for the use, care, and/or processing of a medical device or system. A recommended practice does not address device performance *per se*, but rather procedures and practices that will help ensure that a device is used safely and effectively and that its performance will be maintained.

Although a device standard is primarily directed to the manufacturer, it may also be of value to the potential purchaser or user of the device as a fume of reference for device evaluation. Similarly, even though a recommended practice is usually oriented towards health care professionals, it may be useful to the manufacturer in better understanding the environment in which a medical device will be used. Also, some recommended practices, while not addressing device performance criteria, provide guidelines to industrial personnel on such subjects as sterilization processing, methods of collecting data to establish safety and efficacy, human engineering, and other processing or evaluation techniques; such guidelines may be useful to health care professionals in understanding industrial practices.

In determining whether an AAMI standard or recommended practice is relevant to the specific needs of a potential user of the document, several important concepts must be recognized:

All AAMI standards and recommended practices are *voluntary* (unless, of course, they are adopted by government regulatory or procurement authorities). The application of a standard or recommended practice is solely within the discretion and professional judgment of the user of the document.

Each AAMI standard or recommended practice reflects the collective expertise of a committee of health care professionals and industrial representatives, whose work has been reviewed nationally (and sometimes internationally). As such, the consensus recommendations embodied in a standard or recommended practice are intended to respond to clinical needs and, ultimately, to help ensure patient safety. A standard or recommended practice is limited, however, in the sense that it responds generally to perceived risks and conditions that may not always be relevant to specific situations. A standard or recommended practice is an important *reference* in responsible decision-making, but it should never *replace* responsible decisionmaking.

Despite periodic review and revision (at least once every five years), a standard or recommended practice is necessarily a static document applied to a dynamic technology. Therefore, a standards user must carefully review the reasons why the document was initially developed and the specific rationale for each of its provisions. This review will reveal whether the document remains relevant to the specific needs of the user.

Particular care should be taken in applying a product standard to existing devices and equipment, and in applying a recommended practice to current procedures and practices. While observed or potential risks with existing equipment typically form the basis for the safety and performance criteria defined in a standard, professional judgment must be used in applying these criteria to existing equipment. No single source of information will serve to identify a particular product as "unsafe". A voluntary standard can be used as one resource, but the ultimate decision as to product safety and efficacy must take into account the specifics of its utilization and, of course, cost-benefit considerations. Similarly, a recommended practice should be analyzed in the context of the specific needs and resources of the individual institution or firm. Again, the rationale accompanying each AAMI standard and recommended practice is an excellent guide to the reasoning and data underlying its provision.

In summary, a standard or recommended practice is truly useful only when it is used in conjunction with other sources of information and policy guidance and in the context of professional experience and judgment.

INTERPRETATIONS OF AAMI STANDARDS AND RECOMMENDED PRACTICES

Requests for interpretations of AAMI standards and recommended practices must be made in writing, to the Manager for Technical Development. An official interpretation must be approved by letter ballot of the originating committee and subsequently reviewed and approved by the AAMI Standards Board. The interpretation will become official and representation of the Association only upon exhaustion of any appeals and upon publication of notice of interpretation in the "Standards Monitor" section of the *AAMI News*. The Association for the Advancement of Medical Instrumentation disclaims responsibility for any characterization or explanation of a standard or recommended practice which has not been developed and communicated in accordance with this procedure and which is not published, by appropriate notice, as an *official interpretation* in the *AAMI News*.

Clinical investigation of medical devices for human subjects—Part 1: General requirements

Approved 14 March 2003 by
Association for the Advancement of Medical Instrumentation

Approved 27 March 2003 by
American National Standards Institute, Inc.

Abstract: Defines procedures for the conduct and performance of clinical investigations of medical devices.

Keywords: biological evaluation, medical devices, clinical investigations

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

Association for the Advancement of Medical Instrumentation
1110 N. Glebe Road, Suite 220
Arlington, VA 22201-4795

© 2003 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this draft should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-199-4

Contents

Glossary of equivalent standards.....	v
Committee representation.....	vii
Background of ANSI/AAMI adoption of ISO 10993-1:2003.....	viii
Foreword.....	ix
Introduction.....	x
1 Scope.....	1
2 Normative references	1
3 Terms and definitions	1
4 Justification for a clinical investigation.....	3
5 Ethical considerations.....	3
5.1 Declaration of Helsinki	3
5.2 Improper influence or inducement	4
5.3 Compensation and additional health care.....	4
5.4 Responsibilities	4
6 General requirements.....	4
6.1 Formal agreement(s).....	4
6.2 Qualifications	4
6.3 Clinical investigation plan.....	4
6.4 Design of the clinical investigation	4
6.5 Confidentiality.....	4
6.6 Start of clinical investigation.....	4
6.7 Informed consent	4
6.7.1 General	4
6.7.2 Process of obtaining informed consent.....	5
6.7.3 Information to be provided to the subject for the purpose of obtaining informed consent	5
6.7.4 Informed consent statement	6
6.7.5 Informed consent agreement.....	6
6.8 Suspension or early termination of the clinical investigation.....	6
6.9 Document and data control.....	6
6.10 Accounting for subjects	6
6.11 Access to preclinical and clinical information.....	6
6.12 Auditing	7
7 Documentation.....	7
7.1 General	7
7.2 Clinical investigator's brochure	7
7.3 Other documents.....	7
8 Sponsor	8
8.1 General	8
8.2 Responsibilities of sponsor	8
9 Monitor.....	9
9.1 Responsibilities of monitor	9

10	Clinical investigator	9
10.1	General	9
10.2	Qualification of clinical investigator	9
10.3	Responsibilities of clinical investigator	9
11	Final report.....	11
11.1	Presentation of results	11
11.2	Contents of the final report.....	11

Annexes

A	Suggested procedure for literature review	12
B	Information for the ethics committees	14
C	Final reports of clinical investigations with medical devices	15
	Bibliography	18

Glossary of equivalent standards

International standards adopted in the United States may include normative references to other international standards. For each international standard that has been adopted by AAMI (and ANSI), the table below gives the corresponding U.S. designation and level of equivalency to the international standard. (Note: Documents are sorted by international designation.)

Other normatively referenced international standards may be under consideration for U.S. adoption by AAMI; therefore, this list should not be considered exhaustive.

International designation	U.S. designation	Equivalency
IEC 60601-1-2:2001	ANSI/AAMI/IEC 60601-1-2:2001	Identical
IEC 60601-2-21:1994 and Amendment 1:1996	ANSI/AAMI/IEC 60601-2-21 & Amendment 1:2000 (consolidated texts)	Identical
IEC 60601-2-24:1998	ANSI/AAMI ID26:1998	Major technical variations
ISO 5840:1996	ANSI/AAMI/ISO 5840:1996	Identical
ISO 7198:1998	ANSI/AAMI/ISO 7198:1998/2001	Identical
ISO 7199:1996	ANSI/AAMI/ISO 7199:1996/(R)2002	Identical
ISO 10993-1:1997	ANSI/AAMI/ISO 10993-1:1997	Identical
ISO 10993-2:1992	ANSI/AAMI/ISO 10993-2:1993/(R)2001	Identical
ISO 10993-3:1992	ANSI/AAMI/ISO 10993-3:1993	Identical
ISO 10993-4:2002	ANSI/AAMI/ISO 10993-4:2002	Identical
ISO 10993-5:1999	ANSI/AAMI/ISO 10993-5:1999	Identical
ISO 10993-6:1994	ANSI/AAMI/ISO 10993-6:1995/(R)2001	Identical
ISO 10993-7:1995	ANSI/AAMI/ISO 10993-7:1995/(R)2001	Identical
ISO 10993-8:2000	ANSI/AAMI/ISO 10993-8:2000	Identical
ISO 10993-9:1999	ANSI/AAMI/ISO 10993-9:1999	Identical
ISO 10993-10:2002	ANSI/AAMI BE78:2002	Minor technical variations
ISO 10993-11:1993	ANSI/AAMI 10993-11:1993	Minor technical variations
ISO 10993-12:2002	ANSI/AAMI/ISO 10993-12:2002	Identical
ISO 10993-13:1998	ANSI/AAMI/ISO 10993-13:1999	Identical
ISO 10993-14:2001	ANSI/AAMI/ISO 10993-14:2001	Identical
ISO 10993-15:2000	ANSI/AAMI/ISO 10993-15:2000	Identical
ISO 10993-16:1997	ANSI/AAMI/ISO 10993-16:1997/(R)2003	Identical
ISO 10993-17:2002	ANSI/AAMI/ISO 10993-17:2002	Identical
ISO 11134:1994	ANSI/AAMI/ISO 11134:1993	Identical
ISO 11135:1994	ANSI/AAMI/ISO 11135:1994	Identical
ISO 11137:1995 and Amendment 1:2001	ANSI/AAMI/ISO 11137:1994 and Amendment 1:2002	Identical

International designation	U.S. designation	Equivalency
ISO 11138-1:1994	ANSI/AAMI ST59:1999	Major technical variations
ISO 11138-2:1994	ANSI/AAMI ST21:1999	Major technical variations
ISO 11138-3:1995	ANSI/AAMI ST19:1999	Major technical variations
ISO TS 11139:2001	ANSI/AAMI/ISO 11139:2002	Identical
ISO 11140-1:1995 and Technical Corrigendum 1:1998	ANSI/AAMI ST60:1996	Major technical variations
ISO 11607:2003	ANSI/AAMI/ISO 11607:2000	Identical
ISO 11737-1:1995	ANSI/AAMI/ISO 11737-1:1995	Identical
ISO 11737-2:1998	ANSI/AAMI/ISO 11737-2:1998	Identical
ISO TR 13409:1996	AAMI/ISO TIR 13409:1996	Identical
ISO 13485:1996	ANSI/AAMI/ISO 13485:1996	Identical
ISO 13488:1996	ANSI/AAMI/ISO 13488:1996	Identical
ISO 14155-1:2003	ANSI/AAMI/ISO 14155-1:2003	Identical
ISO 14155-2:2003	ANSI/AAMI/ISO 14155-2:2003	Identical
ISO 14160:1998	ANSI/AAMI/ISO 14160:1998	Identical
ISO 14161: 2000	ANSI/AAMI/ISO 14161:2000	Identical
ISO 14937:2000	ANSI/AAMI/ISO 14937:2000	Identical
ISO 14969:1999	ANSI/AAMI/ISO 14969:1999	Identical
ISO 14971:2000	ANSI/AAMI/ISO 14971:2000	Identical
ISO 15223:2000	ANSI/AAMI/ISO 15223:2000	Identical
ISO 15223/A1:2002	ANSI/AAMI/ISO 15223:2000/A1:2001	Identical
ISO 15225:2000	ANSI/AAMI/ISO 15225:2000	Identical
ISO 15674:2001	ANSI/AAMI/ISO 15674:2001	Identical
ISO 15675:2001	ANSI/AAMI/ISO 15675:2001	Identical
ISO TS 15843:2000	ANSI/AAMI/ISO TIR15843:2000	Identical
ISO TR 15844:1998	AAMI/ISO TIR15844:1998	Identical
ISO TR 16142:1999	ANSI/AAMI/ISO TIR16142:2000	Identical
ISO 25539-1:2003	ANSI/AAMI/ISO 25539-1:2003	Identical

Committee representation

Association for the Advancement of Medical Instrumentation

Biological Evaluation Committee

The adoption of ISO 14155-1:2003 as an American National Standard was initiated by the AAMI Biological Evaluation Committee, which also functions as a U.S. Technical Advisory Group (TAG) to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Clinical Investigations Working Group (U.S. Sub-TAG for ISO/TC 194/WG 4), chaired by Kimber C. Richter, MD, of the U.S. Food and Drug Administration and Nancy J. Stark, PhD, of Clinical Device Group, Inc., played an active part in developing the ISO standard.

At the time this document was published, the **AAMI Biological Evaluation Committee** had the following members:

- Cochairs:* Donald E. Marlowe
Peter W. Urbanski
- Members:* James M. Anderson, MD, PhD, Case Western Reserve University
Eric R. Claussen, PhD, Becton Dickinson & Company
Roger Dabbah, PhD, U.S. Pharmacopeial Convention, Inc.
Lawrence H. Hecker, PhD, Abbott Laboratories
Edward Mueller, MS, Annapolis, MD
Barry F.J. Page, Garner, NC
Melvin E. Stratmeyer, PhD, U.S. Food and Drug Administration/Center for Devices and Radiological Health/OST
Paul J. Upman, PhD, NAMSA
Peter W. Urbanski, Medtronic, Inc.
- Alternates:* Raju G. Kammula, DVM, PhD, U.S. Food and Drug Administration/Center for Devices and Radiological Health/ODE
Donald E. Marlowe, U.S. Food and Drug Administration/Center for Devices and Radiological Health
Sharon J. Northup, PhD, U.S. Pharmacopeial Convention, Inc.

At the time this document was published, the **AAMI Clinical Investigations Working Group** had the following members:

- Cochairs:* Kimber C. Richter, MD
Nancy J. Stark, PhD
- Members:* James M. Anderson, MD, PhD, Case Western Reserve University
Carolyn Braithwaite, Gambro BCT, Inc.
Ioana G. Carabin, MD, Burdock Group
Eric R. Claussen, PhD, Becton Dickinson & Company
Duane R. Dey, Bausch & Lomb, Inc.
Dean Elfath, MD, Baxter Healthcare Corporation
Roobert L. Fuson, MD, Zimmer, Inc.
Joel Gorski, PhD, NAMSA
Sarah E. Moeller, Medtronic, Inc.
Susan Moritz, Boston Scientific Corporation
Patrick J. Parks, MD, PhD, 3M Healthcare
Kimber C. Richter, MD, U.S. Food and Drug Administration/Center for Devices and Radiological Health/OC
Cheryl D. Spencer, Abbott Laboratories
Kenneth R. St. John, PhD, University of Mississippi Medical Center
Nancy J. Stark, PhD, Clinical Device Group, Inc.
Rodney A. White, MD, Harbor-UCLA Medical Center
- Alternates:* Carol Brozek, 3M Healthcare
Stephen P. Costanzo, Bausch & Lomb, Inc.
David W. Eaker, PhD, DABT, Becton Dickinson & Company
Daniel Hamilton, Ross Products (Abbott Laboratories)
Edward Reverdy, PhD, Boston Scientific Corporation
Harold E. Sargent, PhD, Baxter Healthcare Corporation
Russell A. Schenck, PhD, Zimmer, Inc.
Celia Witten, U.S. Food and Drug Administration/Center for Devices and Radiological Health

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.

Background of ANSI/AAMI adoption of ISO 14155-1:2003

As indicated in the foreword to the main body of this document (page ix), the International Organization for Standardization (ISO) is a worldwide federation of national standards bodies. The United States is one of the ISO members that took an active role in the development of this standard.

International standard ISO 14155-1 was developed by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*, to provide procedures for the conduct and performance of clinical investigations of medical devices.

U.S. participation in this ISO TC is organized through the U.S. Technical Advisory Group for ISO/TC 194, administered by the Association for the Advancement of Medical Instrumentation (AAMI) on behalf of the American National Standards Institute (ANSI). The United States made a considerable contribution to this International Standard.

AAMI encourages its committees to harmonize their work with International Standards in the area of biological evaluation of medical devices as much as possible in order to help reduce unnecessary repetition of testing. Upon review of ISO 14155-1, the AAMI Biological Evaluation Committee and the AAMI Clinical Investigations Working Group proposed the adoption of ISO 14155-1:2003 verbatim as a partial revision of ANSI/AAMI/ISO 14155:1996. ISO (and AAMI, through the adoption process) is also issuing 14155-2, covering clinical investigation plans, to complete the revision of 14155:1996.

Several significant changes to the previous edition (14155:1996) were made. New sections have been added for informed consent and IRB/Ethics Committee review, new annexes have been added for literature reviews and case report form design, and the definitions of adverse events and effects have been updated. Also, a second part (14155-2) was created to provide requirements for the preparation of a clinical investigation plan.

AAMI (and ANSI) have adopted other ISO standards. See the Glossary of Equivalent Standards for a list of ISO standards adopted by AAMI, which gives the corresponding U.S. designation and the level of equivalency with the ISO standard.

AAMI and ANSI procedures require that American National Standards be reviewed and, if necessary, revised within five years to confirm currency or reflect technological advances that have occurred since publication, as appropriate.

The concepts incorporated in this standard should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and as new data comes to light.

Suggestions for improving this standard are invited. Comments and suggested revisions should be sent to Standards Department, AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795.

NOTE—Beginning with the ISO foreword on page ix, this American National Standard is identical to ISO 14155-1:2003.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 14155-1 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

This first edition of ISO 14155-1, together with ISO 14155-2, cancels and replaces ISO 14155:1996, which has been technically revised.

ISO 14155 consists of the following parts, under the general title *Clinical investigation of medical devices for human subjects*:

- *Part 1: General requirements*
- *Part 2: Clinical investigation plans*

Introduction

This part of ISO 14155 is intended to be applied worldwide to clinical investigations of medical devices in order to fulfill the technical aspects of the various national, regional, and international regulatory requirements. As the legal regulatory requirements presently differ throughout the world, regulatory specifics have been excluded from the scope of this part of ISO 14155. They are part of national or regional legislative texts and can be referenced in the national or regional forewords, as appropriate.

Clinical investigation of medical devices for human subjects—Part 1: General requirements for biological tests

1 Scope

This part of ISO 14155 defines procedures for the conduct and performance of clinical investigations of medical devices. It specifies general requirements intended to

- protect human subjects,
- ensure the scientific conduct of the clinical investigation,
- assist sponsors, monitors, investigators, ethics committees, regulatory authorities, and bodies involved in the conformity assessment of medical devices.

This part of ISO 14155

- a) specifies requirements for the conduct of a clinical investigation such that it establishes the performance of the medical device during the clinical investigation intended to mimic normal clinical use, reveals adverse events under normal conditions of use, and permits assessment of the acceptable risks having regard to the intended performance of the medical device,
- b) specifies requirements for the organization, conduct, monitoring, data collection, and documentation of the clinical investigation of a medical device,
- c) is applicable to all clinical investigation(s) of medical devices whose clinical performance and safety is being assessed in human subjects.

This part of ISO 14155 is not applicable to *in vitro* diagnostic medical devices.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14155-2, *Clinical investigation of medical devices for human subjects—Part 2: Clinical investigation plans*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1 adverse device effect: Any untoward and unintended response to a medical device.

NOTE 1—This definition includes any event resulting from insufficiencies or inadequacies in the instructions for use or the deployment of the device.

NOTE 2—This definition includes any event that is a result of a user error.

3.2 adverse event: Any untoward medical occurrence in a subject.

NOTE—This definition does not imply that there is a relationship between the adverse event and the device under investigation.

3.3 case report form: Document designed to record all information to be reported to the sponsor on each subject as required by the clinical investigation plan.

3.4 clinical investigation: Any designed and planned systematic study in human subjects undertaken to verify the safety and/or performance of a specific device.

3.5 clinical investigation plan (CIP): Document that states the rationale, objectives, design and proposed analysis, methodology, monitoring, conduct, and record keeping of the clinical investigation.

NOTE—The word “protocol” is often used synonymously with the term “clinical investigation plan.” However, it has many different meanings, some not related to clinical investigations, and these may differ from country to country. Therefore, it is not used in this part of ISO 14155.

3.6 clinical investigator: Individual and/or institution responsible for the conduct of a clinical investigation who and/or that takes the clinical responsibility for the well-being of the subjects involved.

NOTE—Whether this is an individual or an institutional responsibility may depend on national legislation.

3.7 clinical investigator’s brochure: Compilation of the clinical and non-clinical information on the device(s) under investigation that is relevant to the investigation in human subjects.

3.8 clinical performance: Behavior of a specific medical device and/or its performance in relation to its intended use when correctly applied to appropriate subjects.

3.9 coordinating clinical investigator: Clinical investigator who is appointed by the sponsor to coordinate work in a multicenter clinical investigation.

3.10 ethics committee: Independent and properly constituted competent body whose responsibility is to ensure that the safety, well-being, and human rights of the subjects participating in a clinical investigation are protected.

NOTE—For the purposes of this part of ISO 14155, “ethics committee” is synonymous with “research ethics committee” or “institutional review board.” The regulatory requirements pertaining to ethics committees or similar institutions may differ from country to country.

3.11 final report: Description, results, and evaluation of the clinical investigation after its completion.

3.12 informed consent: Legally effective, documented confirmation of a subject’s (or his/her legal guardian or representative) voluntary agreement to participate in a particular clinical investigation after information has been given to the subject on all aspects of the clinical investigation that are relevant to the subject’s decision to participate.

3.13 investigation center (investigation site): Institution or site where the clinical investigation is carried out.

3.14 medical device: Any instrument, apparatus, appliance, material, or other article, whether used alone or in combination, including the software necessary for its proper application, intended by the manufacturer to be used on human beings for the purpose of

- diagnosis, prevention, monitoring, treatment, or alleviation of disease,
- diagnosis, monitoring, treatment, alleviation, or compensation for an injury or handicap,
- investigation, replacement, or modification of the anatomy or of a physiological process,
- control of conception,

and which does not achieve its principal intended action in or on the human body by pharmacological, immunological, or metabolic means, but which may be assisted in its function by such means.

NOTE—The term “medical device” is usually defined by national law. In order to inform the user of this part of ISO 14155, the definition from reference [1] is listed (see Bibliography). More information is given in reference [3].

3.15 monitor: Individual appointed by the sponsor responsible for assessing the investigator’s compliance with the clinical investigation plan and for performing source-data verification.

NOTE—The monitor is also responsible for reporting to the sponsor on the progress of the clinical investigation, including the compliance of the investigators.

3.16 multicenter investigation: Clinical investigation that is conducted according to a single clinical investigation plan and that takes place at two or more sites.

3.17 principal clinical investigator: Clinical investigator responsible for the organization of the clinical investigation at one site.

3.18 serious adverse device effect: Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event or that might have led to any of these consequences if suitable action had not been taken or intervention had not been made or if circumstances had been less opportune.

3.19 serious adverse event: Adverse event that

- a) led to a death,
- b) led to a serious deterioration in the health of the subject that
 - 1) resulted in a life-threatening illness or injury,
 - 2) resulted in a permanent impairment of a body structure or a body function,
 - 3) required in-patient hospitalization or prolongation of existing hospitalization,
 - 4) resulted in medical or surgical intervention to prevent permanent impairment to body structure or a body function.
- c) led to fetal distress, fetal death, or a congenital abnormality or birth defect.

3.20 source data: All information in original and identified records and certified copies of original records of clinical findings, observations, or other activities in a clinical investigation, necessary for the reconstruction and evaluation of the clinical investigation.

3.21 source documents: Original documents, data, and records.

NOTE—This may be, for example, hospital records, laboratory notes, pharmacy dispensing records, copies, or transcriptions certified after verification as being accurate copies, photographic negatives, radiographs, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical investigation.

3.22 sponsor: Individual or organization that takes responsibility for the initiation and/or implementation of a clinical investigation.

NOTE 1—For the purposes of this part of ISO 14155, the word “sponsor” is synonymous with the word “promoter.”

NOTE 2—When a clinical investigator independently initiates, implements, and takes full responsibility for the clinical investigation, the clinical investigator also assumes the role of the sponsor.

3.23 subject: Individual who participates in a clinical investigation, either as a recipient of the device under investigation or as a control.

4 Justification for a clinical investigation

In order to determine the justification and optimal design for a clinical investigation, an objective review of published and available unpublished medical and scientific data and information shall be conducted and documented.

NOTE 1—Guidance for such a literature review is given in Annex A.

The decision to embark upon a clinical investigation of a medical device requires *inter alia* the residual risks to be balanced against the anticipated benefits of the clinical investigation.

NOTE 2—For further information, see ISO 14971 [6].

5 Ethical considerations

5.1 Declaration of Helsinki

The rights, safety, and well-being of clinical investigation subjects shall be protected consistent with the ethical principles laid down in the Declaration of Helsinki. This shall be understood, observed, and applied at every step in the clinical investigation.

5.2 Improper influence or inducement

The sponsor and the clinical investigator(s) shall avoid improper influence or inducement of the subject, the monitor, the clinical investigator(s), or other parties participating in or contributing to the clinical investigation.

5.3 Compensation and additional health care

The sponsor shall state what provision will be made for compensation of subjects in the event of injury arising from participation in the clinical investigation, and this shall be documented. Arrangements for additional health care for subjects required as a result of an adverse device effect shall be made and documented.

NOTE—This may be the subject of national legislation.

5.4 Responsibilities

All parties involved in the conduct of the clinical investigation shall share the responsibility for its ethical conduct in accordance with their respective roles in the investigation.

6 General requirements

6.1 Formal agreement(s)

There shall be agreement(s) between the sponsor, the clinical investigator(s), and other relevant parties that define(s) their responsibilities. All formal agreements shall be recorded in writing and signed by all parties involved.

6.2 Qualifications

All parties participating in the conduct of the clinical investigation shall be appropriately qualified by education and/or experience to perform their tasks.

6.3 Clinical investigation plan

A clinical investigation plan shall be compiled in accordance with ISO 14155-2.

6.4 Design of the clinical investigation

The clinical investigation shall be designed to evaluate whether the device is suitable for the purpose(s) and the population(s) for which it is intended. It shall be designed in such a way as to ensure that the results obtained have clinical relevance and scientific validity and will support the clinical investigation objectives.

6.5 Confidentiality

At all times throughout the clinical investigation, confidentiality shall be observed by all parties involved. All data shall be secured against unauthorized access. Privacy and confidentiality of information about each subject shall be preserved in the reports and any publication of the clinical investigation data.

Lists of subjects' names and identifying information should, wherever possible, be maintained separately from case report forms.

6.6 Start of clinical investigation

No clinical investigation shall start until

- a) a clinical investigation plan has been written and signed,
- b) the opinion and/or approval of the ethic(s) committee(s) has been obtained,
- c) regulatory clearance or approval, if applicable, has been obtained.

6.7 Informed consent

6.7.1 General

Informed consent shall be obtained in writing and documented before a subject is enrolled into the clinical investigation.

NOTE—The consent form usually consists of an information part and an approval/signature part. These two parts can be either combined in one document (patient information and consent form) or separated into a patient information sheet and a patient consent form.

6.7.2 Process of obtaining informed consent

The process of obtaining informed consent shall

- a) avoid any coercion of or undue influence of subjects to participate,
- b) not waive or appear to waive subject's legal rights,
- c) use language that is non-technical and understandable to the subject or his/her legal representative,
- d) provide ample time for the subject to consider participation,
- e) include dated signatures of the subject or the subject's legal representative and of the clinical investigator,
- f) show how informed consent will be obtained and recorded in circumstances in which the subject is unable to give it,

NOTE—A subject intended for the participation in a clinical investigation may be unable to make the necessary decisions (fetus, infant, child, and juvenile; the seriously ill or unconscious; mentally ill; mentally handicapped). In such circumstances, informed consent can be given only by the legal guardian or representative.

- g) be documented in the clinical investigation plan.

6.7.3 Information to be provided to the subject for the purpose of obtaining informed consent

At least the following information shall be provided in writing and in non-technical language that is understandable to the subject (or the subject's legal representative):

- a) description/purpose:
 - 1) the investigation involves research;
 - 2) the objective of the investigation;
 - 3) the anticipated duration and involvement of subject participation in the investigation;
 - 4) description of the device under investigation;
 - 5) description of procedures, emphasizing any that are experimental.
- b) foreseeable risks:
 - 1) description of any foreseeable risks and inconveniences;
 - 2) possible side effects.
- c) potential benefits:
 - 1) description of potential benefits to the subjects;
 - 2) description of potential benefits to others.
- d) alternative therapy:
 - 1) information on alternative treatments or procedures available.
- e) confidentiality:
 - 1) statement that subject participation is confidential;
 - 2) statement that subject allows access to medical records by regulatory authorities and sponsor's delegates;
 - 3) statement that investigation results may be published without disclosing the subject's identity.
- f) compensation (medical/financial):
 - 1) information about provisions for compensation in the event of injury arising from participation in the clinical investigation and additional health care to be provided to subjects as a result of an adverse device effect;
 - 2) information on financial compensation for participation, if applicable.

- g) questions and/or termination:
 - 1) whom to contact with questions about the investigation;
 - 2) whom to contact in the event of injury;
 - 3) circumstances under which subject's participation may be terminated by the investigator, if applicable.
- h) new findings:
 - 1) statement that new findings relevant to the subject's confirmed participation shall be made available.

6.7.4 Informed consent statement

The statement of informed consent shall contain the following in writing:

- a) statement that subject's participation is voluntary;
- b) statement that refusal of participation incurs no penalty for the subject;
- c) statement that discontinuation at any time incurs no penalty for the subject;
- d) statement on possible consequences of withdrawal;
- e) acknowledgment of the information provided.

6.7.5 Informed consent agreement

In signing the consent form, the subject or his/her legal representative shall

- a) agree to participate in and comply with the clinical investigation,
- b) agree to his/her personal physician being informed of his/her participation, or state his/her disagreement to the release of this information,
- c) agree to the use of his/her relevant personal data for the purpose of the clinical investigation.

6.8 Suspension or early termination of the clinical investigation

If an investigation is terminated prematurely or suspended, the sponsor shall promptly inform the clinical investigators/investigation centers of the termination or suspension and the reason(s) for this. The ethics committee shall also be informed promptly and provided with the reason(s) for the termination or suspension by the sponsor or by the clinical investigator/investigation centers.

NOTE—Depending on the type of investigation, regulatory authorities and the personal physicians of the subjects may also need to be informed.

6.9 Document and data control

All documents and data shall be produced and maintained in such a way as to ensure control of documents and data and to protect the subject's privacy as far as reasonably practicable.

A case report form shall be developed to capture the data for the individual subject required by the clinical investigation plan.

6.10 Accounting for subjects

All subjects enrolled in the clinical investigation (including those withdrawn from the investigation or lost to follow-up) shall be accounted for and documented.

6.11 Access to preclinical and clinical information

Each clinical investigator taking part in the clinical investigation shall have the right of access to the relevant preclinical and safety information. All information given shall be kept confidential.

The monitor shall have access to the source documents and other information needed to ensure investigator compliance with the clinical investigation plan and applicable rules and regulations, and to assess the progress of the clinical investigation.

6.12 Auditing

The clinical investigator(s) shall allow auditing of their clinical investigation procedures.

7 Documentation

7.1 General

Documentation in 7.2 and 7.3 shall be prepared before commencement of the clinical investigation. The information supplied to the clinical investigator shall be documented.

7.2 Clinical investigator's brochure

The clinical investigator's brochure shall contain

- a) a summary of the literature and an evaluation supporting the rationale for the intended use of the device and the design of the clinical investigation,
- b) a general description of the device and its components in accordance with ISO 14155-2,
- c) a description of the mechanism of action of the device, along with supporting scientific literature including, if relevant, the manufacturer's instructions for use and installation,

This should include possible risks, contra-indications, warnings, etc., for the device.

- d) a description of the intended clinical performance,
- e) a description of the materials used in the device,
- f) a summary and evaluation of the *in vitro* and/or *ex vivo* and/or *in vivo* data relevant to the device, including preclinical data such as biological studies, non-clinical laboratory studies, and any animal studies,
- g) a summary of relevant previous clinical experience with the device and with other devices with similar features,
- h) a list of International Standards, if any, complied with in full or in part,
- i) results of the risk analysis.

The clinical investigator's brochure shall be updated throughout the course of the clinical investigation as significant new information becomes available and shall be communicated to the investigators.

7.3 Other documents

As a minimum, the following documents shall be maintained in investigator and/or sponsor files:

- a) the clinical investigation plan;
- b) a current, signed, and dated curriculum vitae of each of the clinical investigators;
- c) the name(s) of the institution(s) in which the clinical investigation will be conducted;
- d) the ethics committee opinion and/or approval, in writing, and relevant correspondence;
- e) correspondence with authorities as required by national legislation;
- f) the agreement between the principal and coordinating investigator(s) and the sponsor;
- g) appropriate insurance certificates, if applicable;
- h) informed consent forms and other information provided to the subjects;
- i) case report forms;
- j) forms for reporting adverse events and adverse device effects;
- k) names/contact addresses of monitor(s).

8 Sponsor

8.1 General

Prior to initiating a clinical investigation, the sponsor shall define, establish, allocate, and communicate all investigation-related duties and functions. The sponsor shall ensure documentation of the compliance of the investigator, sponsor, and monitor with this part of ISO 14155, the applicable clinical investigation plan and subsequent amendments and with all applicable regulatory requirements through a quality system.

8.2 Responsibilities of sponsor

The sponsor shall

- a) select the clinical investigator(s) and investigation center(s) for the particular investigation, and if appropriate, a coordinating clinical investigator,
- b) select and appoint a monitor for the clinical investigation or otherwise assume the responsibilities of the monitor,
The ultimate responsibility for monitoring remains with the sponsor even if those activities are outsourced or delegated. Instructions should be available from the sponsor to the monitor on how to handle non-compliances and missing data.
- c) prepare, and keep up to date, the clinical investigator's brochure,
- d) provide the clinical investigator with the clinical investigation plan and subsequent approved amendments, and with the clinical investigator's brochure,
- e) sign the approved clinical investigation plan,
- f) supply fully characterized devices that are the subject of the clinical investigation,
- g) ensure that appropriate information and/or training is given to the clinical investigator, if necessary, in the use of the device in accordance with the clinical investigation plan,
- h) ensure that all deviations from the clinical investigation plan are reviewed with the appropriate clinical investigator(s) and reported in the case report forms and the final report for the clinical investigation,
- i) ensure that all adverse events and all adverse device effects are reported and reviewed with the clinical investigator(s) and, where appropriate, that all serious adverse events and all serious adverse device effects are reported to the relevant authorities and ethics committee(s) and/or safety monitoring committee(s),
- j) during the course of the clinical investigation, inform in writing all principal clinical investigators about all serious adverse events and all serious adverse device effects occurring in (multicenter) clinical investigations that have been reported to the sponsor. This information shall be sent to the clinical investigator(s) based on perceived risk,
- k) promptly inform the clinical investigator(s) when a clinical investigation is prematurely terminated or suspended and, where applicable, inform the regulatory authority(ies) and ethics committee(s) of the termination or suspension and the reason(s) for the termination or suspension,
- l) inform the clinical investigator(s) of the developmental status of the device and the requirements necessary to verify the performance and the safety of the device,
- m) review and approve any deviation from the clinical investigation plan and take any appropriate corrective or preventive actions,
- n) collect, store, keep secured, and ensure completion by the relevant parties of the following documents:
 - 1) all documents listed in Clause 7 (documentation);
 - 2) copies of signed and dated case report form(s);
 - 3) records of any adverse events and adverse device effects reported to the sponsor during the clinical investigation;
 - 4) any statistical analyses and underlying supporting data;
 - 5) final report of the clinical investigation.

- o) ensure accurate device accountability and traceability systems.

9 Monitor

9.1 Responsibilities of monitor

The monitor shall verify that

- a) compliance with the clinical investigation plan is maintained and any deviation from the clinical investigation plan is discussed with the clinical investigators, documented, and reported to the sponsor,
- b) the device is being used according to the clinical investigation plan, and if modifications are required either to the device or its method of use or to the clinical investigation plan, this need is reported to the sponsor,
- c) the clinical investigator(s) has(have) and continue(s) to have staff and facilities to conduct the clinical investigation safely and effectively,
- d) the clinical investigator(s) has(have) and continue(s) to have access to an adequate number of subjects and devices,
- e) signed and dated informed consent forms have been obtained from each subject at the time of enrollment and before any study-related procedures are undertaken,
- f) the data in the case report forms are complete, are recorded in a timely manner, and are consistent with the source data,
- g) the procedures for recording and reporting adverse events and adverse device effects to the sponsor are followed,
- h) there is a process in place for device accountability and traceability and that it is maintained,
- i) maintenance and calibration of the equipment relevant for the assessment of the clinical investigation is performed and documented,
- j) subject withdrawal and/or non-compliance is documented and discussed with the clinical investigator and reported to the sponsor,
- k) findings of non-compliance or required modifications shall be reviewed with the investigator and disclosed in a written monitoring report to the sponsor.

10 Clinical investigator

10.1 General

If the clinical investigator is an institution, it shall appoint a person with the qualifications and responsibilities of the clinical investigator mentioned in 10.2 and 10.3.

10.2 Qualifications of clinical investigator

The clinical investigator shall be

- a) an appropriately qualified practitioner legally entitled to practice,
- b) experienced in the field of application and trained in the use of the device under consideration,
- c) familiar with the background and requirements of the clinical investigation methodology,
- d) trained in the proper method of obtaining informed consent.

10.3 Responsibilities of clinical investigator

The clinical investigator shall be responsible for the day-to-day conduct of the clinical investigation as well as for the safety and well-being of the human subjects involved in the clinical investigation. The clinical investigator shall

- a) have the resources to conduct the clinical investigation properly,
- b) ensure that conducting the clinical investigation will not give rise to a conflict of interest,
- c) obtain from the sponsor the information that the clinical investigator judges essential about the device and be familiar with this information,

- d) be well acquainted with the clinical investigation plan before signing it,
- e) support the monitor and auditor, if applicable, in their activities to verify compliance with the clinical investigation plan, to perform source data verification, and to correct the case report form where inconsistencies or missing values are identified,
- f) discuss with the sponsor and the monitor any question of modification of the clinical investigation plan and obtain the written approval of the sponsor,
- g) make sure that the clinical investigation plan is followed by all responsible for the conduct of the clinical investigation at his/her institution. Any deviation shall be documented and reported to the sponsor,
- h) make the necessary arrangements to ensure the proper conduct and completion of the clinical investigation,
- i) make the necessary arrangements for emergency treatment, as needed, to protect the health and welfare of the subject,
- j) ensure that appropriate ethics committee approval has been received to start the clinical investigation at his/her center,

NOTE—Examples of information for the ethics committee are given in Annex B.

- k) provide the results from the ethics committee to the sponsor,
- l) inform the ethics committee and ask for its opinion and/or approval regarding any significant change in the clinical investigation plan that has been approved by the sponsor and the reasons for the change,
- m) inform the ethics committee about any serious adverse device effects,
- n) inform the sponsor about all adverse events and adverse device effects in a timely manner,
- o) endeavor to ensure an adequate recruitment of subjects,
- p) ensure that the subject has adequate information to give informed consent,
- q) ensure that informed consent is obtained and documented,
- r) ensure that clinical records shall be clearly marked to indicate that the subject is enrolled in a particular clinical investigation. If appropriate, subjects enrolled in the clinical investigation shall be provided with some means of showing their participation in the investigation, together with identification and compliance information for concurrent treatment measures. Contact address/telephone numbers shall be given.

If appropriate, the subject's personal physician should, with the subject's agreement, be informed.

- s) provide subjects with well-defined procedures for any emergency situation and safeguard the subject's interest. Under these circumstances deviations from the clinical investigation plan shall not require the prior approval of the sponsor or the ethics committee. Such deviations shall not be considered as a breach of agreement but shall be documented and reported to the sponsor,
- t) ensure that information that becomes available as a result of the clinical investigation that may be of importance to the health of the subject and the continuation in the clinical investigation shall be made known to the sponsor and, if pertinent to the safety or well-being of the subject, the subject and the subject's private clinician,
- u) inform the subject and/or the subject's physician about any premature termination or suspension of the clinical investigation with a rationale for the study termination,
- v) have primary responsibility for the accuracy, legibility, and security of all clinical investigation data, documents, and patient records at his/her investigation site both during and after the clinical investigation. The case report form shall be signed by the clinical investigator(s). Any alteration of the data shall be made only by authorized personnel, and initialed and dated by the same, the original entry being retained for comparison,
- w) ensure that the basic data are kept for the minimum time specified in the clinical investigation plan,
- x) be responsible for the supervision and assignment of duties to all responsible for the conduct and evaluation of the clinical investigation for the clinical investigation center involved,
- y) ensure that all devices that are the subject of the clinical investigation are accounted for.

The quantity of the devices received should be reconciled with the quantities of devices used, discarded, or returned.

11 Final report

11.1 Presentation of results

A final report of the clinical investigation shall be completed, even if the clinical investigation is prematurely terminated.

11.2 Contents of the final report

A final report shall be presented in written form. This shall be signed by the sponsor and the coordinating investigator (if appointed) and the principal clinical investigator(s) in each center and made available, upon request, to all the clinical investigators and the ethics committee(s).

The final report of the clinical investigation shall include thorough identification of the device(s), a description of the methodology and design of the clinical investigation, any deviations from the clinical investigation plan, data analysis with any statistical analysis, and a critical appraisal in relation to the aims of the investigation.

The final report shall take into account all data from each investigation center/site and for all enrolled subjects. No subject shall be identifiable from either the final report or published results.

All clinical investigators shall have the opportunity to review and comment on the final report. The sponsor shall maintain records confirming that investigators have been provided with the final report for review and any comments. If a clinical investigator does not agree with all or parts of the final report, his/her comments shall be recorded and communicated to the other investigators.

If the coordinating investigator or any of the principal clinical investigator(s) does not sign the final report, a justification shall be provided for not signing the final report.

NOTE—Further guidance for the content of the final report is given in Annex C.

Annex A

(informative)

Suggested procedure for literature review

A.1 Introduction

A review and evaluation of the literature is essential for justification and planning of any clinical investigation of a medical device. The aim of such a review is to provide a basis for drafting the clinical investigation plan in order to determine scientific background for the clinical investigation. It also provides essential information for assessing risk/benefits and achieving the ethical conduct of the planned investigation.

NOTE—Such a literature review may also be helpful to assess whether the relevant clinical data available in the literature are sufficient to demonstrate safety and performance of the device in question without the need to generate further data from a specifically designed clinical investigation or conclude that the available data are not sufficient.

Performing a literature survey is a scientific activity that should be done with rigor and objectivity, and should allow for verification by third parties.

A.2 Methodology

A.2.1 General

Prior to performing the literature review, a plan should be established for the identification, selection, collation, and review of all available studies/data. This plan should be documented and preferably be based on recognized practice for systematic review of the scientific literature.

A.2.2 Objective(s)

The objective(s) of the literature review should be clearly defined. The types of studies that are relevant to these objective(s) should be specified, taking into account any already well-established knowledge of the device.

A.2.3 Selection criteria for documents

The criteria for selecting or excluding data should be defined with an appropriate rationale. Published data should be taken from recognized scientific publications. All available unpublished relevant data should also be taken into account in order to avoid publication bias. All data should be referenced.

The literature review should state the sources of literature and data, and the extent of the searches of databases or other compilations of information.

A.2.4 Assessment of documents

A literature review should clearly assess the quality of the documents and the extent to which the literature relates to the specific characteristics and features of the device under consideration, taking into account the intended use of the device.

The following shall be considered:

- a) similarity of the device in the selected documents to the device under consideration based on technology, critical performance, design, and principles of operation, so that the applicability of the literature can be assessed;
- b) the patient or study populations in the documents and the medical purpose, indications for use, and severity and type of disease or condition compared to those intended for the device under assessment;
- c) conditions of use of the device in the documents and the intended use of the device in question.

The literature review should make an assessment of the significance and weight of studies of different designs and between published and unpublished data. If unpublished data is being included in the assessment, the literature review will need to distinguish between the significance that is attached to it.

Factors include

- 1) whether the author's conclusions are substantiated by the available data,

- 2) whether the literature reflects the current medical practice and state-of-the-art technologies,
- 3) whether references are taken from recognized scientific publications and whether or not they have been reported in peer-reviewed journals,
- 4) the extent to which the published literature is the outcome of a study/studies that have followed scientific principles.

Ideally, evidence should be generated from a controlled clinical investigation, properly designed cohort- or case-controlled investigation, well-documented case histories conducted by appropriate experts, or reports of significant experience with the marketed device.

A.2.5 Critical evaluation of the literature

The literature review should contain a critical evaluation of the literature.

After documents are obtained and assessed, the selection criteria that are applied and the exclusion of any documents from this critical evaluation must be justified. A review is then completed as it relates to the device in question and its intended use, and a structured report of the review should be written, consisting of

- a) a short description of the medical device, including its intended functions, the type of device, technology and features, and a description of the intended method of use,
- b) an analysis of all the selected literature and data, both favorable and unfavorable,
- c) a critical evaluation of the hazards, associated risks, and appropriate safety measures for patients, medical staff, and third parties,
- d) a description of the methods of weighting the different papers and the statistical methods of analysis employed, taking into account the assessment methods, the type and duration of study, and the heterogeneity of the population included within the study. Particular attention should be given to circumstances where there are repeated publications on the same group of patients by the same authors, in order to avoid over-weighting multiple publications of the same test subjects,
- e) a list of publications appropriately cross-referenced in the evaluation,
- f) a conclusion with a justification, including an assessment of any probable benefit to health from the use of the device as intended by the manufacturer, against probable risks of injury or illness from such use, taking account of the "state of the art." The conclusions should make it clear how the objectives of the literature review have been met and identify any gaps in the evidence necessary to cover all relevant aspects of safety and performance. If a clinical investigation is considered necessary, the conclusion should also give details on the relevant objectives and design of such an investigation, based on results of the literature review;
- g) the signature(s) of the reviewer(s) and date.

Annex B

(informative)

Information for the ethics committees

The following information can be of relevance for the ethics committee:

- a) an assessment of the scientific merit and justification of the clinical investigation project and of the investigation plan proposal;
- b) a summary of how the health status of subjects may be affected;
- c) an assessment of possible risks, methods, and facilities proposed for dealing with them;
- d) an assessment of any expected discomfort or distress;
- e) proposed method of supervision of the clinical investigation, and the qualifications and experience of the clinical investigator(s) to conduct the clinical investigation;
- f) all details of the proposed informed consent procedure, including an information sheet written in non-technical language that the subject or his/her guardian or legal representative can understand, including the aims, expected benefits for the subject and/or others, risks, inconveniences, and an explanation of alternatives;
- g) an outline of procedures that will ensure confidentiality;
- h) documentation of how informed consent will be obtained from the subject and recorded in emergency circumstances in which the subject is unable to give consent;
- i) document(s) provided for subject's identification and compliance information for concurrent treatment measures and for any emergency situation;
- j) a copy of the patient insurance policy when legally relevant;
- k) the clinical investigation plan and any amendments;
- l) the clinical investigator's brochure;
- m) progress report and the final report;
- n) all reports on serious adverse events and all adverse device effects.

Annex C

(informative)

Final reports of clinical investigations with medical devices

C.1 General

This annex specifies the structure and contents of clinical investigation reports.

C.2 Title page

The title page should contain the following information:

- a) title of investigation;
- b) identification of the medical devices, including names, models, etc., as relevant for complete identification;
- c) name of sponsor;
- d) clinical investigation plan (CIP) identification;
- e) statement indicating whether the investigation was performed in accordance with this part of ISO 14155;
- f) date of report;
- g) author(s) of report.

C.3 Summary

A structured abstract should be provided, presenting the essentials of the study in the following sections:

title, introduction, objectives, subjects, methods, results, conclusions.

The key dates should be given, including the investigation initiation dates (first subject in) and investigation completion date (last subject out) or date of early termination, if applicable.

C.4 Table of contents

C.5 Introduction

A brief statement placing the study in the context of the development of the medical device and an identification of guidelines followed in the development in the clinical investigation plan should be provided.

C.6 Materials and methods

C.6.1 Device description

Summary description of the device and its intended use. Any modification of the device during the investigation should be described.

C.6.2 Clinical Investigation Plan (CIP) summary

A summary of the CIP should be provided. Any modification of the CIP during the investigation should be described. The summary should include a brief description of

- a) the clinical investigation objectives,
- b) the investigation design,
 - 1) type of investigation
 - 2) investigation endpoints
- c) ethical considerations,
- d) data quality assurance,

- e) subject population for the investigation,
 - 1) inclusion/exclusion criteria
 - 2) sample size
- f) treatment and treatment allocation,
- g) investigation variables,
- h) concomitant medications/treatments,
- i) duration of follow-up,
- j) statistical analysis.
 - 1) investigation hypothesis or pass/fail criteria
 - 2) sample size calculation
 - 3) statistical analysis methods

C.7 Results

This section should contain summary information with a description of the analysis and results.

This section should include

- a) the investigation initiation date,
- b) the investigation completed/suspension date,
- c) the disposition of patients/devices,
- d) the patient demographics,
- e) CIP compliance,
- f) the analysis, which includes
 - 1) safety report comprising a summary of all adverse events and adverse device effects (device-related or not) seen in the investigation, including a discussion of the severity, treatment needed, resolution, and assessment by the investigator of relation to treatment provided as part of the investigation,
 - 2) performance analysis provided for in the CIP,
 - 3) any needed subgroup analyses for special populations (i.e., gender, racial/cultural subgroups) as appropriate,
 - 4) a description of how missing data (including patients lost to follow-up or withdrawn for any reason) were dealt with in the analysis.

C.8 Discussion and overall conclusions

The performance and safety results of the study and the relationship of risks and benefits should be briefly summarized and discussed. The clinical relevance and importance of the results should also be discussed in the light of other existing data. Any specific benefits or special precautions required for individual subjects or at-risk groups and any implications for the conduct of future studies should be identified.

C.9 Abbreviated terms and definitions

A list of abbreviated terms and definitions of specialized or unusual terms should be provided.

C.10 Ethics

It should be confirmed that the CIP and any amendments to it were reviewed by an ethics committee. A list of all consulted ethic committees should be given in an annex to the report (see C.13).

C.11 Investigators and administrative structure of investigation

A brief description of the organization of the study should be included in the report. A list of investigators should be given in an annex, including their affiliations. The name and address of the sponsor's representative should be provided.

C.12 Signature block

The signature provisions given in 11.2 should apply.

C.13 Annex to the report

There should be an annex to the report containing the following:

- a) the CIP, including amendments;
- b) a list of investigators and their institutions of affiliation;
- c) a list of other parties involved (e.g., core labs, contract research organizations (CROs), experts, etc.);
- d) a list of monitors;
- e) a list of ethics committees;
- f) a tabulation of all relevant data sets, including all CIP deviations, all adverse events and adverse device effects, withdrawals, and discontinuations.

Bibliography

- [1] European Directives on medical devices, 93/42/EEC from 14 June 1993 and on active implantable medical devices, 90/385, EEC from 20 July 1990, as amended.
- [2] ISO 14971, *Medical devices—Application of risk management to medical devices*.
- [3] *Essential Principles*—Global Harmonization Task Force, 1999.
- [4] International Conference on Harmonisation, *Harmonised Tripartite Guideline for Good Clinical Practice*, 2nd edition, May 1996.
- [5] *Ethical principles for medical research involving human subjects*, World Medical Association, available at <<http://www.wma.net/e/approvedhelsinki.html>>.
- [6] ISO 10993 (all parts), Biological evaluation of medical devices.